BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 7914841)

  • 1. Increased concentrations of soluble tumor necrosis factor receptor 75 but not of soluble intercellular adhesion molecule-1 are associated with the decline of CD4+ lymphocytes in HIV infection.
    Zangerle R; Fuchs D; Sarcletti M; Gallati H; Reibnegger G; Wachter H; Dierich MP; Möst J
    Clin Immunol Immunopathol; 1994 Sep; 72(3):328-34. PubMed ID: 7914841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased levels of serum intercellular adhesion molecule 1 in HIV infection are related to immune activation.
    Diez-Ruiz A; Kaiser G; Jäger H; Birkmann J; Tilz GP; Wachter H; Fuchs D
    Int Arch Allergy Immunol; 1993; 102(1):56-60. PubMed ID: 8104576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum HIV-1 RNA levels compared to soluble markers of immune activation to predict disease progression in HIV-1-infected individuals.
    Zangerle R; Steinhuber S; Sarcletti M; Dierich MP; Wachter H; Fuchs D; Möst J
    Int Arch Allergy Immunol; 1998 Jul; 116(3):228-39. PubMed ID: 9693271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor necrosis factor alpha and soluble tumor necrosis factor receptors in individuals with human immunodeficiency virus infection.
    Zangerle R; Gallati H; Sarcletti M; Wachter H; Fuchs D
    Immunol Lett; 1994 Jul; 41(2-3):229-34. PubMed ID: 8002043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value for survival of soluble tumor necrosis factor receptors p55 and p75 during zidovudine-containing treatment in symptomatic human immunodeficiency virus type 1 infection.
    Frissen PH; Weverling GJ; Endert E; Jansen J; Sauerwein HP; Lange JM
    J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Aug; 12(5):482-8. PubMed ID: 8757425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma levels of viro-immunological markers in HIV-infected and non-infected Ethiopians: correlation with cell surface activation markers.
    Messele T; Brouwer M; Girma M; Fontanet AL; Miedema F; Hamann D; Rinke de Wit TF
    Clin Immunol; 2001 Feb; 98(2):212-9. PubMed ID: 11161977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased serum concentrations of soluble tumor necrosis factor receptors in HIV-infected individuals are associated with immune activation.
    Zangerle R; Gallati H; Sarcletti M; Weiss G; Denz H; Wachter H; Fuchs D
    J Acquir Immune Defic Syndr (1988); 1994 Jan; 7(1):79-85. PubMed ID: 7903382
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased plasma concentrations of HDL cholesterol in HIV-infected individuals are associated with immune activation.
    Zangerle R; Sarcletti M; Gallati H; Reibnegger G; Wachter H; Fuchs D
    J Acquir Immune Defic Syndr (1988); 1994 Nov; 7(11):1149-56. PubMed ID: 7932082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Markers for disease progression in intravenous drug users infected with HIV-1.
    Zangerle R; Fuchs D; Reibnegger G; Fritsch P; Wachter H
    AIDS; 1991 Aug; 5(8):985-91. PubMed ID: 1685652
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting clinical progression or death in subjects with early-stage human immunodeficiency virus (HIV) infection: a comparative analysis of quantification of HIV RNA, soluble tumor necrosis factor type II receptors, neopterin, and beta2-microglobulin. Multicenter AIDS Cohort Study.
    Stein DS; Lyles RH; Graham NM; Tassoni CJ; Margolick JB; Phair JP; Rinaldo C; Detels R; Saah A; Bilello J
    J Infect Dis; 1997 Nov; 176(5):1161-7. PubMed ID: 9359714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1.
    Fahey JL; Taylor JM; Detels R; Hofmann B; Melmed R; Nishanian P; Giorgi JV
    N Engl J Med; 1990 Jan; 322(3):166-72. PubMed ID: 1967191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and laboratory predictors of survival in Gambian patients with symptomatic HIV-1 or HIV-2 infection.
    Whittle H; Egboga A; Todd J; Corrah T; Wilkins A; Demba E; Morgan G; Rolfe M; Berry N; Tedder R
    AIDS; 1992 Jul; 6(7):685-9. PubMed ID: 1354448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Soluble tumor necrosis factor receptors as surrogate markers for the assessment of zidovudine treatment in asymptomatic HIV-1 infection.
    Godfried MH; van der Poll T; Mulder JW; Weverling GJ; Endert E; Lange JM; Sauerwein HP
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Dec; 10(5):531-9. PubMed ID: 8548332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Weight loss in HIV-1 infection is associated with immune activation.
    Zangerle R; Reibnegger G; Wachter H; Fuchs D
    AIDS; 1993 Feb; 7(2):175-81. PubMed ID: 8096702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Abnormal levels of circulating adhesion molecules in HIV-1 infection with characteristic alterations in opportunistic infections.
    Nordøy I; Aukrust P; Müller F; Frøland SS
    Clin Immunol Immunopathol; 1996 Oct; 81(1):16-21. PubMed ID: 8808636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune activation markers and AIDS prognosis.
    Osmond DH; Shiboski S; Bacchetti P; Winger EE; Moss AR
    AIDS; 1991 May; 5(5):505-11. PubMed ID: 1677808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune changes in HIV-1 infection: significant correlations and differences in serum markers and lymphoid phenotypic antigens.
    Bass HZ; Nishanian P; Hardy WD; Mitsuyasu RT; Esmail E; Cumberland W; Fahey JL
    Clin Immunol Immunopathol; 1992 Jul; 64(1):63-70. PubMed ID: 1376654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Serum levels of soluble tumor necrosis factor receptors as markers for disease progression of human immunodeficiency virus infection].
    Hattori M; Tateyama M; Oishi T; Miyasaka S; Fukutake K
    Rinsho Byori; 1997 Nov; 45(11):1085-90. PubMed ID: 9396350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between surrogate markers, viral load, and disease progression in HIV-1 infection.
    Lafeuillade A; Tamalet C; Pellegrino P; de Micco P; Vignoli C; Quilichini R
    J Acquir Immune Defic Syndr (1988); 1994 Oct; 7(10):1028-33. PubMed ID: 7916049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum nitrite plus nitrate in infection with human immunodeficiency virus type-1.
    Zangerle R; Fuchs D; Reibnegger G; Werner-Felmayer G; Gallati H; Wachter H; Werner ER
    Immunobiology; 1995 Jun; 193(1):59-70. PubMed ID: 7590863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.